Business
Curaleaf Completes Buyout of Remaining Stake in Germany's Four 20 Pharma
Curaleaf Holdings, Inc (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer products in cannabis, has completed the buyout of the remaining 45% stake not previously owned in Four 20 Pharma GmbH, a fully EU-GMP and GDP licensed German producer and distributor of medical cannabis. Four 20 Pharma is recognized for its high-quality cultivation, pharmaceutical-grade processing, and comprehensive distribution network across Germany and select European
About this update from Curaleaf Holdings, Inc.
[{"type":"text","content":"STAMFORD, Conn., April 30, 2026 /PRNewswire/ -- Curaleaf Holdings, Inc (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer products in cannabis, has completed the buyout of the remaining 45% stake not previously owned in Four 20 Pharma GmbH, a fully EU-GMP and GDP licensed German producer and distributor of medical cannabis. Four 20 Pharma is recognized for its high-quality cultivation, pharmaceutical-grade processing, and comprehensive distribution network across Germany and select European markets, serving nursing homes, pharmacies, and research institutions. The company's commitment to compliance, patient care, and scientific rigor positions it as a cornerstone of Europe's medical cannabis ecosystem.","length":841,"tagName":"p"},{"type":"image","alt":"Curaleaf Holdings, Inc. Logo (PRNewsfoto/Curaleaf Holdings, Inc.)","displaySize":"","headline":null,"caption":"Curaleaf Holdings, Inc. Logo (PRNewsfoto/Curaleaf Holdings, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":153,"url":"https://media.zenfs.com/en/cnwgroup.com/2a374296622fa3cd87850e28410bae1c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hnLvHyTLzKSpjOE0ittt7Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI3MA--/https://media.zenfs.com/en/cnwgroup.com/2a374296622fa3cd87850e28410bae1c","width":400,"height":153}},"href":"https://mma.prnewswire.com/media/2379626/image124200_ID_1dd17c09c26d_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The full acquisition of Four 20 Pharma strengthens Curaleaf's vertically integrated, global supply chain, from owned cultivation sources in Portugal and Canada through to licensed distribution across Germany, delivering a true seed-to-patient quality guarantee and full oversight at every stage. Since the initial agreement in 2022, Curaleaf and Four 20 Pharma have collaborated closely to expand patient access, advance research initiatives, and streamline the international medical cannabis supply chain, validating a data-driven approach to education, cultivation, and product development.","length":596,"tagName":"p"},{"type":"text","content":""Completing this buyout of the remaining stake in Four 20 Pharma reinforces our commitment to Europe...